GlassScriptPhysician profile
Esra Demirel
NPI 1164926093
$613.53
in general payments reported to CMS, 2019-2025
12 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.41 · 2023: $91.79 · 2024: $240 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $205.18 | 2025 | Veozah |
| Applied Medical Resources Corporation | $109.07 | 2024 | Gelpoint V-Path |
| Meditrina | $71.29 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $54.79 | 2023 | Lynparza |
| Organon LLC | $28.34 | 2024-2025 | Nexplanon |
| Alexion Pharmaceuticals, INC. | $26.45 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $22.41 | 2022 | |
| Evofem Biosciences, INC. | $20.57 | 2025 | Solosec, Phexx, Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $19.49 | 2025 | |
| Abbvie INC. | $19.08 | 2023 | Orilissa |
| Corium, LLC | $18.94 | 2024 | Azstarys |
| Sumitomo Pharma America, INC. | $17.92 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esra Demirel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.